Loading stock data…
NPCE
$16.90-0.17 (-1.00%)
Market ClosedLast close May 4
NeuroPace, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeuroPace, Inc. in the Healthcare sector is trading at $16.90. The stock is currently near its 52-week high of $18.98, remaining 29.0% above its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why NPCE maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.90
Potential Upside
5%
Whystock Fair Value$17.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant fo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$572.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-136.31%
Volume
Today's trading volume
129,856
Recent News
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative
NeuroPace’s analyst narrative has been refreshed around a price target anchored to an unchanged model fair value of $19.88 per share, indicating that the core valuation framework remains intact. The $1 adjustment in the price target reflects updated views on how the company might execute on profitability, with bullish and cautious perspectives assessing those assumptions differently. As you read on, you will see how these price target changes fit into the broader story and what to monitor as...
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions
NeuroPace is back on investor radar as analysts update their models and lift the fair value price target from US$19.43 to about US$19.88. Some see this roughly US$0.45 move as better aligned with revised expectations around the company’s growth trajectory. Others point out that it may leave less room for error if forecasts do not play out as modeled. As you read on, you will see how these shifts shape the evolving narrative and what to watch next in the story. Analyst Price Targets don't...